IL1512 / Ildong - LARVOL DELTA

A SELECTIVE AND ORALLY BIOAVAILABLE CXCR7 MODULATOR'S IMPACT ON BLEOMYCIN-INDUCED SKIN FIBROSIS IN A MOUSE MODEL (EULAR 2024) - "IL1512 demonstrated a potent efficacy equal to or greater than Imatinib in bleomycin-induced skin fibrosis mouse model. We propose that IL1512 as the first CXCR7 modulator may have therapeutic potential in Systemic sclerosis disease."

Preclinical • Cardiovascular • Coronary Artery Disease • Fibrosis • Immunology • Oncology • Scleroderma • Systemic Sclerosis • ACKR3

The effect of the novel selective and orally bioavailable CXCR7 modulator in carbon tetrachloride (CCl4)-induced liver fibrosis using mouse model (EASL-ILC 2024) - "Prophylactic treatment with IL1512 in a CCl 4-induced liver fibrosis model demonstrated a potent efficacy equal to or greater than Elafibranor. This study identified IL1512 as the first CXCR7 modulator showing notable efficacy in an animal model of liver fibrosis."

Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • ACKR3

Discovery of the Novel Selective and Orally Bioavailable CXCR7 Modulator for the Treatment of Idiopathic Pulmonary Fibrosis (ATS 2024) - " In the mouse IPF model, C57BL/6 mice were subjected to a single intra-tracheal (IT) dose of bleomycin (BLM, 1. IL1512 has been identified as a novel selective CXCR7 modulator. Prophylactic treatment with IL1512 in a BLM-induced IPF model exhibited robust efficacy superior to pirfenidone. Moreover, IL1512 demonstrated a good PK profile, delivering anti-fibrotic efficacy at a lower dose than pirfenidone, even with once-daily dosing."

Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • ACKR3 • COL1A1 • TGFB1

iLeadBMS releases positive preclinical results of pulmonary fibrotic disease treatment candidate at US meet (Korea Biomedical Review) - "iLeadBMS...has unveiled promising research results for its novel idiopathic pulmonary fibrosis (IPF) treatment, IL1512, at the American Thoracic Society (ATS) 2024 conference, which is taking place in San Diego, Calif., from last Friday to Wednesday....In preclinical studies using a bleomycin-induced pulmonary fibrosis model, IL1512 administered once daily demonstrated dose-dependent improvements. Also, it performed as well as or better than existing standard treatments without causing significant side effects, including weight loss, a common issue with existing therapies."

Preclinical • Idiopathic Pulmonary Fibrosis • Pulmonary Disease